SciBX: Science-Business eXchange Contents: January 05 2012, Volume 5 / Issue 1

TABLE OF CONTENTS January 5 2012, Volume 5 / Issue 1 Analysis Cover Story Translational Notes Targets and Mechanisms Tools The Distillery: Therapeutics Cancer Cardiovascular disease Dermatology Endocrine/metabolic disease Infectious disease Musculoskeletal disease Neurology Ophthalmic disease Autoimmune disease The Distillery: Techniques Assays and screens Chemistry Drug platforms SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top No place like inflammasome Lauren Martz doi:10.1038/scibx.2012.1 Researchers at Virginia Commonwealth University have found that inhibiting inflammasome formation with P2X7 antagonists could help prevent heart failure following acute myocardial infarction. The findings point to a repurposing opportunity for P2X7 antagonists that companies have in the clinic for inflammatory indications. Full Text | PDF Translational Notes Top AstraZeneca's compound interest Lev Osherovich doi:10.1038/scibx.2012.2 The U.K.'s Medical Research Council has partnered with AstraZeneca to make the pharma's shelved compounds available to academics investigating basic disease mechanisms. A first call for proposals is in progress. Full Text | PDF Targets and Mechanisms Top Fine-tuning mGluRs Lev Osherovich doi:10.1038/scibx.2012.3 UPenn and MIT teams have independently converged on mGluRs as players in ADHD and autism. The findings suggest agonizing mGluRs in patients with ADHD or certain forms of autism and antagonizing the targets in other forms of autism. Full Text | PDF Tools Top Eau de fluorescence Joanne Kotz doi:10.1038/scibx.2012.4 NCI and University of Tokyo researchers have developed a fluorescent probe that can be sprayed onto tissue during surgery to detect small metastases. The researchers plan to validate the method in fresh surgical tissue from ovarian cancer patients in preparation for an IND. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top DEAD box polypeptide 58 (DDX58; RIG-I); interferon induced with helicase C domain 1 (IFIH1; MDA5) doi:10.1038/scibx.2012.5 Mouse studies suggest activating RIG-I or MDA5 could help treat MS. Full Text | PDF Sphingosine 1-phosphate receptor 1 (S1PR1; S1P1; EDG1) doi:10.1038/scibx.2012.6 Mouse studies suggest an S1P1 antagonist might help treat RA and other autoimmune indications. Full Text | PDF Cancer Top Neuroblastoma Ras viral oncogene (NRAS); lysophospholipase I (LYPLA1; APT-1) doi:10.1038/scibx.2012.7 Cell culture studies suggest inhibiting APT-1 could help treat mutant NRAS–driven leukemias. Full Text | PDF c-Myc (MYC); SUMO1 activating enzyme subunit 1 (SAE1); ubiquitin-like modifier activating enzyme 2 (UBA2; SAE2) doi:10.1038/scibx.2012.8 Patient tissue and mouse studies suggest inhibiting SAE1 and/or SAE2 could help treat MYC-driven breast cancers. Full Text | PDF Vascular cell adhesion molecule-1 (VCAM-1); integrin α4 (VLA-4; CD49D) doi:10.1038/scibx.2012.9 In vitro, mouse and human studies suggest inhibiting VCAM-1 or its receptor VLA-4 could help prevent bone metastases in breast cancer. Full Text | PDF Checkpoint kinase 1 (Chk1) doi:10.1038/scibx.2012.10 Mouse and cell culture studies suggest Chk1 inhibitors should not be combined with histone deacetylase (HDAC) inhibitors to treat cancer. Full Text | PDF Thioredoxin; thioredoxin reductases doi:10.1038/scibx.2012.11 Mouse studies identified peptidomimetic inhibitors of the thioredoxin reductase pathway that could help treat cancer. Full Text | PDF MEK; BCR-ABL tyrosine kinase doi:10.1038/scibx.2012.12 Cell culture and mouse studies suggest combining Tasigna nilotinib with MEK inhibitors could help treat drug-resistant CML. Full Text | PDF Bone morphogenetic protein 7 (BMP7; OP-1) doi:10.1038/scibx.2012.13 Mouse studies suggest BMP7 could help prevent bone metastasis in prostate cancer. Full Text | PDF Cardiovascular disease Top G protein–coupled bile acid receptor 1 (GPBAR1; TGR5) doi:10.1038/scibx.2012.14 Mouse studies suggest agonizing TGR5 could help prevent atherosclerosis. Full Text | PDF Rho kinase doi:10.1038/scibx.2012.15 In vitro and mouse studies suggest inhibiting rho kinase could help prevent atherosclerosis progression. Full Text | PDF Dermatology Top Focal adhesion kinase (FAK) doi:10.1038/scibx.2012.16 Full Text | PDF Endocrine/metabolic disease Top Histone deacetylase (HDAC); glucocerebrosidase (GBA; GCase) doi:10.1038/scibx.2012.17 In vitro studies suggest HDAC inhibitors could help treat Gaucher's disease. Full Text | PDF Infectious disease Top PD-1 receptor (PDCD1; PD-1; CD279); programmed cell death 1 ligand 1 (CD274 molecule; PD-L1; B7-H1); lymphocyte-activation gene 3 (LAG3; CD223) doi:10.1038/scibx.2012.18 Patient sample and mouse studies suggest inhibiting PD-L1 and LAG3 could help treat malaria. Full Text | PDF Heme oxygenase decycling 1 (HMOX1; HO-1; Hsp32) doi:10.1038/scibx.2012.19 Mouse studies suggest inhibiting HO-1 could protect against Salmonella infection in patients exposed to malaria. Full Text | PDF Musculoskeletal disease Top Guanine nucleotide binding protein (G protein) α-inhibiting activity polypeptide 2 (GNAI2) doi:10.1038/scibx.2012.20 Mouse and tissue culture studies suggest increasing GNAI2 signaling could help promote muscle repair and regeneration. Full Text | PDF Neurology Top β-Amyloid (Aβ) doi:10.1038/scibx.2012.21 In vitro studies suggest grafted antibodies that recognize AD-associated Aβ fibrils could help treat AD. Full Text | PDF Metabotropic glutamate receptor subtype 5 (mGluR5; GRM5); mGluR7 (GRM7); mGluR8 (GRM8) doi:10.1038/scibx.2012.22 A genomewide association study suggests agonizing mGluR5, mGluR7 or mGluR8 could be useful for treating ADHD. Full Text | PDF Metabotropic glutamate receptor subtype 5 (mGluR5; GRM5) doi:10.1038/scibx.2012.23 Studies in mice suggest agonizing mGluR5 may help treat a hereditary form of ASD caused by tuberous sclerosis complex (TSC). Full Text | PDF Ophthalmic disease Top Vimentin (VIM) doi:10.1038/scibx.2012.24 A study in mice suggests decreasing VIM expression could help reduce fibrosis resulting from corneal wounds. Full Text | PDF Distillery: Techniques Assays and screens Top High throughput sequencing of tumor tissue to guide clinical trial enrollment doi:10.1038/scibx.2012.25 High throughput sequencing of tumor tissue from patients with advanced cancer could help guide clinical trial enrollment. Full Text | PDF Quantification of minimal residual disease in chronic lymphocytic leukemia (CLL) following hematopoietic stem cell transplant doi:10.1038/scibx.2012.26 High throughput measurement of minimal residual disease in CLL following hematopoietic stem cell transplant could improve early intervention to prevent disease relapse. Full Text | PDF Real-time classification of glioma tumors with mass spectrometry–based lipid profiling doi:10.1038/scibx.2012.27 A mass spectrometry–based method for profiling lipids in glioma tissue samples could enable classification of brain tumors during surgery. Full Text | PDF Chemistry Top Selective arylation of imidazoles to synthesize Tasigna nilotinib and its analogs doi:10.1038/scibx.2012.28 N1-selective palladium-catalyzed arylation of imidazoles could be used to synthesize Tasigna nilotinib and its analogs. Full Text | PDF Drug platforms Top Prophylactic vaccination with antibody-expressing adenoviral transgenes doi:10.1038/scibx.2012.29 An adenoviral vector encoding pathogen-neutralizing antibodies could help prevent viral infections. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.